Skip to main content
. Author manuscript; available in PMC: 2014 Mar 14.
Published in final edited form as: Antibodies (Basel). 2012 Jul 4;1(2):149–171. doi: 10.3390/antib1020149

Figure 4.

Figure 4

IT Immunocytokine effects agains primary (injected) and distant tumors. A/J mice (5 per group) received NXS2 (106 s.c. on day 0) in the abdomen (primary tumor). A 2nd NXS2 injection (106 s.c.) was placed on the flank on d4 (distant tumor). The primary tumor received 50 µL PBS or 15 µg hu14.18-IL2 IT on d7-11, while the distant tumor was not treated. A: Tumor volume of primary tumors (p = 0.001, day 16). Day 0 = implantation of the primary tumor. B: Tumor volume of distant tumors (p = 0.007, day 16). Day 0 = implantation of the distant tumor. C: A/J mice (3 per group) received 106 NXS2 cells on d0 in the abdomen. Mice were treated with 15 µg hu14.18-IL2 IT or s.c. into the flank at a site away from the tumor (p = 0.04, days 13–16). (Adapted from Johnson et al, 2008 [91]).